



Esmolol In Multimodal Therapy: Optimizing Hemodynamic Stability And Analgesia In Surgery

Kisha Cadet 1, Adaku Onwuka 2, Savreen Rangi 3
American University of Antigua College of Medicine

Introduction

Importance of Hemodynamic Stability & Analgesia

- Critical for optimizing cardiovascular responses in surgical and critical care.
- Helps control cardiovascular responses.
- E for Emergency (IV infusion)

Esmolol's Mechanism & Benefits

- Rapid rate and blood pressure. Onset and short duration allow precise control over the heart.
- Reduces myocardial oxygen demand, perioperative tachycardia, and hypertension

Methods

Study Selection

- An initial search for “Esmolol” and “combination” identified 161 clinical trials in the Cochrane Library. Patients (3–75 years) requiring hemodynamic management during
- 45 duplicates (PubMed and Embase) were removed, leaving 116 studies for screening.

Study Characteristics

17 studies, 942 patients across various surgical settings (cardiac, laparoscopic, perioperative). **Control Group: 471 Esmolol Combination Group: 471**

Data Synthesis

Analysis performed using SPSS V29.

Descriptive Statistics: frequency distributions, Mean, and standard deviation.

Inferential Statistics

Random-effects meta-analysis (mean differences & standardized mean differences with 95% CI).

Risk ratios (RR) for categorical variables (e.g., brady-cardia, PONV)


Heterogeneity ($I^2 > 50\%$)

Publication bias: Assessed via Egger's test & funnel plots.
Significance threshold: $p < 0.05$

Results

Pain Management with Esmolol (VAS scores)


- Significantly **reduces** postoperative pain
- **Enhances** patient comfort
- **Lowers** need for additional analgesics
- **Esmolol & Lidocaine in Reducing Postoperative Agitation (Ji 2019):**
- Significantly reduced agitation compared to other groups ($P < 0.05$).
- **VAS Scores:** Esmolol group: 0.00 (no pain) vs. Control group: 4.00.
- **Esmolol:** Beta-blocker that stabilizes hemodynamics, reduces catecholamine-induced agitation. 0
- **Lidocaine:** Provides analgesic and anti-inflammatory effects



Nausea and Vomiting (PONV Relative Risk Reduction)

Clinical Significance


- Lowers incidence of postoperative nausea and vomiting (PONV).
- Supports Esmolol's role in multimodal anesthesia.
- Helps reduce opioid-related adverse effects.



Agitation Scores

Esmolol & Lidocaine in Reducing Postoperative Agitation (Ji 2019):

- Significantly reduced agitation compared to other groups ($P < 0.05$).
- **VAS Scores:** Esmolol group: 0.00 (no pain) vs. Control group: 4.00.
- **Esmolol:** Beta-blocker that stabilizes hemodynamics, reduces catecholamine-induced agitation.
- **Lidocaine:** Provides analgesic and anti-inflammatory effects.



Discussion

Esmolol-based combination therapies reduce intraoperative anesthetic and opioid needs. Optimizes cardiovascular control by modulating sympathetic responses. Mean Arterial Pressure: Cohen's $d = 0.84$ ($p = 0.03$). Heart Rate: Cohen's $d = 1.45$. Reduction in heart rate and blood pressure can be particularly advantageous in procedures requiring controlled hypotension, such as orthopedic, maxillofacial, and laparoscopic surgeries. Esmolol adjunct therapy significantly lowered the incidence of PONV compared to control groups, with relative risk reductions of 40% and 46.7%. It supports multimodal anesthesia strategies to minimize opioid-related side effects. Ji (2019): Patients receiving Esmolol with local anesthetics achieved complete pain relief (VAS = 0.00) vs. Control (VAS = 4.00). Combined with Lidocaine, reduces postoperative agitation through synergistic β_1 -blockade and sodium channel inhibition. Mild bradycardia observed; incidence is low and manageable. Emphasizes the need for careful dosing and monitoring in high-risk patients.

Conclusion

This systematic review and meta-analysis provide compelling evidence supporting the integration of Esmolol in combination therapy for surgical and critical care applications.

That Esmolol: Enhances hemodynamic stability, reduces anesthetic and opioid consumption, improves recovery outcomes by minimizing postoperative nausea, pain, and agitation.

Future Research Should Focus On: Optimizing dosing regimens, evaluating Esmolol's efficacy in diverse patient populations, exploring its role in non-surgical critical care settings, investigating its potential opioid-sparing effects, Impact on inflammatory responses could provide new insights into its broader clinical applications.

References

1. Alonso-Castro AJ, Zapata-Bustos R, Domínguez F, García-Carrancá A, Salazar-Olivo LA. Magnolia dealbata Zucc. and its active principles, honokiol and magnolol, stimulate glucose uptake in murine and human adipocytes using the insulin-signaling pathway. *Phytomedicine*. 2011;18(11):926-933. doi:10.1016/J.PHYMED.2011.02.0152.
2. Ollila A, Vikatmaa L, Sund R, Pettilä V, Wilkman E. Efficacy and safety of intravenous esmolol for cardiac protection in non-cardiac surgery. A systematic review and meta-analysis. *Ann Med*. 2019;51(1):17-27. doi:10.1080/07853890.2018.1538565
3. Celebi N, Cizmeci EA, Canbay O. [Intraoperative esmolol infusion reduces postoperative analgesic consumption and anaesthetic use during septorhinoplasty: a randomized trial]. *Rev Bras Anesthesiol*. 2014;64(5):343-349. doi:10.1016/J.BJAN.2013.10.013
4. Bhawna, Bajwa SJS, Lalitha K, Dhar P, Kumar V. Influence of esmolol on requirement of inhalational agent using entropy and assessment of its effect on immediate postoperative pain score. *Indian J Anaesth*. 2012;56(6):535-541. doi:10.4103/0019-5049.104570